Clinical Trial Update: QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

This update describes a Phase 1 trial of QL1706 as second-line therapy for advanced hepatocellular carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• QL1706

Snippet

Sponsor: Wan-Guang Zhang | Conditions: HCC - Hepatocellular Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING